Siglec10 as an Immunosuppressive and Tumorgenesis Signature for Prediction of Survival Prognosis in Gliomas

Background Glioma is a type of tumor occurring in central nervous system. Specific factors mutations and molecular abnormalities are used to conduct glioma classification and clinical decision in recent decade. Siglec10 is a member of sialic acid binding immunoglobulin superfamily. Methods We analyzed the siglec10 expression in glioma patients with immunohistochemical (IHC) staining method and evaluated the survival prognosis. Bioinformatic datasets including TCGA and CGGA were used to validate the IHC results. Functional enrichment analysis including GO, KEGG, and GSEA were conducted to study the related mechanism of siglec10, either. Results High siglec10 expression had shorter survival prognosis than low siglec10 expression in patients especially with malignant gliomas. Bioinformatic datasets including TCGA and CGGA validated the IHC results and discovered the expression of siglec10 was higher in malignant subtype than benign subtype of gliomas. So, siglec10 contributes to the poor prognosis of gliomas. Furthermore, the related mechanisms of siglec10 in gliomas were investigated by functional enrichment analysis including GSEA, GO, and KEGG analysis. Siglec10 was correlated with inflammatory mediators, inflammatory cells, and inflammatory pathways in gliomas. Conclusions Siglec10 might take part in the immune response in tumor microenvironment to induce the progression and metastasis of glioma. This study showed siglec10 was a biomarker in glioma and it might be the potential target of glioma immunotherapy in the future.